Jan 13 (Reuters) - X4 Pharmaceuticals Inc XFOR.O:
X4 PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE MAVORIXAFOR IN EUROPE, AUSTRALIA, AND NEW ZEALAND
TO RECEIVE €28.5 MILLION UPFRONT, UP TO €226 MILLION IN MILESTONES
TO SUBMIT MAA TO EMA FOR MAVORIXAFOR IN WHIM SYNDROME
Source text: ID:nGNX503rCz
Further company coverage: XFOR.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.